Details
Category: Volume 10 Issue 10 October 2022
Hits: 664

Title: Prophylactic Propranalol In Prevention of Retinopathy of Prematurity in Premature Neonates

Authors: Dr Bismilla Mansuri, Dr Shaista Parween, Dr Subhash Valinjkar

 DOI: https://dx.doi.org/10.18535/jmscr/v10i10.23

Abstract

Retinopathy of prematurity (ROP) is important cause of preventable blindness and ocular disabilities in premature neonates.

Objectives: The current study is done to determine the role of prophylactic propranalol in prevention of retinopathy of prematurity in premature neonates (25-36 wks) and to compare the incidence of ROP in premature neonates receiving oral propranalol in those not receiving oral propranalol.

Material and Methods: This was a single centric observational prospective comparative study. The sample size of this study was 100, divided into 2 groups A and B. Group A = neonates in whom propranalol was given and Group B = neonates in whom propranalol was not given. Neonates in Group A were given oral propranalol 0.5mg/kg/day 12hourly for 14 days. ROP screening was done after 4 weeks of post menstrual age.

Results: Progression of ROP was significantly less (16%) in neonates who were given propranalol (Group A) prophylactically as compared to neonates in whom propranalol was not given (36%) Group B. Majority of neonates in Group A required no intervention (88%) as compared to those without propranalol therapy (64%) Group B.

Conclusion: Our study concludes that use of prophylactic propranalol reduces progression of ROP to higher stages as well as requirement of intervention.

Keywords: Propranalol, Neonate, ROP and Blindness.

References

  1. Subadra J, Anand R, Kumar H, Mangat D, Rajvardhan A, Lingam G. Programme Planning and Screening Strategy in Retinopathy of Prematurity. Indian J Ophthalmol 2003;51:89-99.
  2. Stephen RJ, Schachat AP, Murphy RB: Retina 2nd edition Vol II. Mosby Year Book Inc St.Louis;Baltimore;1447-1471
  3. Aravind J, Devi L, Krishna R, Agarwal P. Retinopathy of Prematurity. International Journal of Science and Researc. 2018; 8(10):471-82.
  4. Gopal L, Sharma T, Ramachandran S. Retinopathy of Prematurity-a study .Ind J Ophthalmol 43:59-62,199
  5. Ferrara N, Davis‐Smyth T. The biology of vascular endothelial growth factor. Endocrine Reviews. Endocrine Society. 1997;18(1):4‐25.
  6. Asthon N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. British Journal of Ophthalmology 1954;38(7):397‐432.
  7. Chen J, Joyal JS, Hatton CJ, Juan AM, Pei DT, Hurst CG. Propranolol inhibition of β‐adrenergic receptor does not suppress pathologic neovascularization in oxygen‐induced retinopathy. Investigative Ophthalmology & Visual Science 2012; 53(6):2968‐77.
  8. Mutlu FM, Sarici SU. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. International Journal of Ophthalmology 2013;6(2):228‐36.
  9. Casini G, Dal Monte M, Fornaciari I, Filippi L, Bagnoli P. The β‐adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Progress in Retinal and Eye Research 2014;42:103‐29.
  10. Léauté‐Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. New England Journal of Medicine 2008;358(24):2649‐51.
  11. Manunza F, Syed S, Laguda B, Linward J, Kennedy H, Gholam K, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. British Journal of Dermatology 2010;162(2):466‐8. 
  12. Praveen V, Vidavalur R, Rosenkrantz TS, Hussain N. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics 2009; 123(3):e484‐9.
  13. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013;131(1):128‐40.
  14. Terry TL. Fibroblastic Overgrowth of Persistent Tunica VasculosaLentis in Infants Born Prematurely: II. Report of Cases-Clinical Aspects. Trans Am Ophthalmol Soc 1942; 40: 262-284
  15. Gilbert C, Rahi J, Eckstein M, O’Sullivan J, Foster A. Retinopathy of prematurity in middle-income countries. Lancet 1997; 350: 12-14
  16. Szewczyk TS. Retrolental fibroplasia; etiology and prophylaxis. Am J Ophthalmol 1952; 35: 301-311
  17. Gilbert C. Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008; 84:77‑82.
  18. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994; 35(1):101-11.
  19. Charan R, Dogra MR, Gupta A, Narang A. Incidence of retinopathy of prematurity in a neonatal care unit. Indian J Ophthalmol1995;43:123-6
  20. Bas AY, Demirel N, Koc E, Isik DU, Hirfanoglu IM, Tunc T, on behalf of the TR-ROP Study Group. Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units. Br J Ophthalmol2018;102:1711–1716
  21. Ahuja AA, V. Reddy YC, Adenuga OO, Kewlani D, Ravindran M, Ramakrishnan R. Risk factors for retinopathy of prematurity in a district in South India: A prospective cohort study. Oman J Ophthalmol 2018;11:33-7
  22. Alajbegovic-HalimicJ ,Zvizdic D, Alimanovic-Halilovic E, Dodik I, Duvnjak S. Risk Factors for Retinopathy of Prematurity in Premature Born Children . Med Arh. 2015; 69(6): 409-413
  23. MitsiakosG ,Papageorgiou A. Incidence and factors predisposing to retinopathy of prematurity in inborn infants less than 32 weeks of gestation. HIPPOKRATIA 2016, 20, 2: 121-126
  24. Dhaliwal CA, Fleck BW, Wright E, Graham C, McIntosh N. Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. 2009;94(3):193-195
  25. Wang ZH, Li YY, Liu ZM. Birth weight and gestational age on retinopathy of prematurity in discordant twins in China.Int J Ophthalmology.2014;7(4):663-667
  26. Manzoni P, Farina D, Maestri A, Giovannozzi C, Leonessa ML, Arisio R, GomiratoG.Mode of delivery and threshold retinopathy of prematurity in pre-term ELBW neonates. Acta Paediatrica.2007; 96(2), 221–226.
  27. Martini D, Dal Monte M, Ristori C, Cupisti E, Mei S, Fiorini P, et al. Antiangiogenic effects of β2 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 2011;119:1317–29.
  28. Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M, Fortunato P et.al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011;52:155-170
  29. Filippi L, Cavallaro G, Fiorini P, Daniotti M, Benedetti V, Cristofori G et.al. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr. 2010;10:83. 
  30. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Tung B, Redford M. Early Treatment for Retinopathy of Prematurity Cooperative Group. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol. 2010;128:663-671
  31. Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Am J Ophthalmol. 2013;155:150-158.e1
  32. Dogra MR, Katoch D, Dogra M. An Update on Retinopathy of Prematurity (ROP).Indian J Pediatr. 2017; 84(12):930-936.
  33. Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013 Mar; 98(2):F170-4.
  34. Eldweik L, Mantagos IS. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity. Semin Ophthalmol. 2016; 31(1-2):163-8.
  35. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011 Feb 17; 364(7):603-15.
  36. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology 2015;122:1008-15
  37. McGillick EV, Orgeig S, Morrison JL. Structural and molecular regulation of lung maturation by intratracheal vascular endothelial growth factor administration in the normally grown and placentally restricted fetus. J Physiol2016;594:1399-420.
  38. Korkmaz L, Baştuğ O, Ozdemir A, Korkut S, Karaca C, Akin MA.et.al.The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index. Curr Eye Res.2017;42(1):88-97
  39. Filippi L, Cavallaro G, Berti E, Padrini L, Araimo G, Regiroli G et.al. Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study. Front. Pediatr. 2019;7:180
  40. Ozturk MA, Korkmaz L. The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: Which newborn and when?. International ophthalmology.2019;39 (9):1921-30.

Corresponding Author

Dr Bismilla Mansuri

M.D Paediatrics Junior Resident, Department of Paediatrics, Grant Government Medical College, Mumbai